Please assess the completion status of the following clinical trial:

Trial Title: EASI Access II --- Follow-up Study to the EASI Access Trial

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Subjects will be at least 18 years of age and have none of the following conditions:~  * pregnancy (negative urine pregnancy test to be performed before study participation),~ * diabetes, or coagulopathic (including taking any anticoagulants);~* Subjects cannot be taking steroids or other immunosuppressants.~* Because of the potential for reduced hyaluronidase effectiveness, the study excludes patients taking more than 80 mg daily aspirin, as well as any patients taking ACTH, antihistamines, or estrogen other than in oral contraceptive preparations.~* Subjects will not be required to fast before the study, but will not allowed to eat or drink during the EASI infusion or the phlebotomy sampling time frame.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: t

Study Arms:
- EASI (Type: EXPERIMENTAL): Subjects will undergo placement of EASI catheters. All subjects in whom EASI catheters are placed, will receive Human Recombinant Hyaluronidase (HRH) as part of the EASI placement. (No subject will receive HRH, other than as part of EASI catheter placement.)

Based on this trial design, predict the completion outcome and termination type (if applicable).